- The breakthrough approval expands the existing indication of Jardiance ® to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that ...

Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction PRESS ...

In the phase III EMPEROR-Preserved trial, among nearly 6,000 patients with chronic HF with preserved ejection fraction (HFpEF), empagliflozin was able to slow kidney function decline over the 172-week ...

Two widely available medicines can safely improve brain health in those with early Alzheimer’s disease, a new study has found ...

The federal government will add a medicine for chronic kidney disease into the Pharmaceutical Benefits Scheme. More than ...

A clinical trial from Wake Forest University School of Medicine shows that two widely available medications, the diabetes ...

- FDA approval marks a significant breakthrough for the approximately 3 million adults in the U.S. with heart failure with preserved ejection fraction, which has been classified as "the single largest ...

- Empagliflozin is the first and only SGLT2 inhibitor approved for this patient population- More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. Jardiance is not ...

Jardiance (empagliflozin; Boehringer Ingelheim and Lilly) The approval was based on data from the phase 3 EMPEROR-Preserved trial. The Food and Drug Administration (FDA) has approved Jardiance ® ...

- The positive opinion is based on the landmark EMPEROR-Preserved Phase III trial, which showed significant outcomes in patients with heart failure with left ventricular ejection fraction over 40% 1 - ...

Jardiance is a diabetes medication that manages blood glucose levels, it is also used as a weight loss treatment. The active drug, Empagliflozin, although not technically a weight loss medication, ...

- More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. RIDGEFIELD, Conn. and INDIANAPOLIS, June 21, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has ...